NCT02665195: Prospective Registry Of MultiPlex Testing (PROMPT).Check study listings or contact the study team to see if you are eligible. The following are risk-management studies enrolling people with inherited mutations. Colonoscopy every 5 years beginning at age 40 (or 5-10 years earlier than the age of diagnosis of a close relative with colon cancer).Men should speak with their doctor about the benefits and risks of screening. There are no current guidelines on breast cancer screening for men with a CHEK2 mutation.Experts recommend consideration of mastectomy be based on family history of breast cancer. There is not enough evidence of benefit from risk-reducing mastectomy (RRM) for women with CHEK2 mutations.Consider annual breast MRI with contrast beginning at age 30-35 or 5-10 years younger than the earliest age of diagnosis in the family.Annual mammogram beginning at age 40 or 5-10 years younger than the earliest age of diagnosis in the family (but no later than age 40).You can learn more about risk management options in our section on Screening and Risk Reduction by Cancer Type. The National Comprehensive Cancer Network (NCCN) provides risk management guidelines for men and women with CHEK2 mutations. We recommend that you speak with a genetics expert who can look at your personal and family history of cancer and can help you determine the best risk-management plan. Risk management for people with inherited CHEK2 mutations